DR-TB STAT

An Activist’s Guide to Bedaquiline (Sirturo)

The guide highlights important safety and efficacy data reported thus far and offers advocacy recommendations for activists to take forward.

Read More →

Activists: Call on your countries to use bedaquiline-based regimens to treat TB

The Global Coalition of TB Activists (GCTA), Treatment Action Group (TAG) and the DR-TB Scale-Up Treatment Action Team (DR-TB STAT) developed a letter template to help activists call for bedaquiline-based, injectable-free regimens for the treatment of drug-resistant TB in their countries.

Read More →

Webinar on implementing an injectable-free regimen for drug-resistant TB - materials now available online

Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB), the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) and TB Proof hosted a webinar on 16 August 2018 on implementing an injectable-free regimen for drug-resistant TB.

Read More →

Webinar: Implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB

Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB) and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) will host a webinar on 16 August 2018 at 10 am EDT / 4 pm South Africa / 5 pm Kenya on implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB (DR-TB) in light of the new World Health Organization (WHO) policy brief on DR-TB regimens.

Read More →

Webinar: Implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB

Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB) and DR-TB STAT will host a webinar on 1 August 2018 at 10 am New York / 4pm South Africa / 5pm Kenya on implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB.

Read More →

New guide to shorter regimen for treating drug-resistant TB

DR-TB STAT + TAG brief: Is Shorter Better? Understanding the Shorter Regimen For Treating Drug-Resistant Tuberculosis

Read More →

New guide: Your rights and TB care

An innovative and important new TB resource – Know Your Rights: Tuberculosis Prevention, Diagnosis, and Treatment Guide.

Read More →

Webinar: The results are in! Now what? - webinar materials now available online

The first ever phase III trials for multidrug-resistant TB (MDR-TB) finally yielded results. Treatment Action Group (TAG), ACTION, and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) presented the results in a webinar held on 12 December 2017. The webinar explored implications for the field, from the delamanid C213 trial and the STREAM trial to evaluate the shorter regimen for MDR-TB.

Read More →

Webinar: The results are in! Now what?

Exploring the implications of the delamanid phase III and STREAM trial results

Read More →

Phase III clinical trial results at the 48th Union World Conference on Lung Health: Implications for the field

Preliminary results from two phase III drug-resistant TB (DR-TB) clinical trials were presented at the 48th Union World Conference on Lung Health: stage 1 of the STREAM trial and the Otsuka 213 delamanid trial.

Read More →

Page 1 of 2 · Total posts: 10

1 2 Last→